SNMMI Clinical Trials Network Research Series for Technologists: Clinical Research Primer—Use of Imaging Agents in Therapeutic Drug Development and Approval

Representative coronal small-animal PET images of control animal imaged with ¹⁸F-AH114726 at baseline and after displacement with 1 mg/kg dose of flumazenil. (Reprinted with permission of (26).)

¹⁸F-FDG PET maximum-intensity projections (A–C), axial PET images (D–F), and axial CT images (G–I) through pelvis in patient with metastatic GIST. Normal physiologic ¹⁸F-FDG uptake is seen in urinary collecting system in both kidneys (kd), in myocardium (my), and in bladder (bl). (A) Intense ¹⁸F-FDG uptake is seen in left lower pelvis and contiguous to right proximal ureter (TU) at baseline before imatinib therapy, consistent with metastatic GIST. (B) Resolution of abnormal ¹⁸F-FDG uptake is noted in both tumor masses as early as 1 wk after treatment. (C) Continuous metabolic response to imatinib is seen in this patient 2 mo after initiation of therapy despite presence of residual mass on CT. (Reprinted with permission of (29).)

¹⁸F-florbetapir (Amyvid) amyloid PET images at baseline and 1 y after aducanumab treatment, showing amyloid plaque reduction after different doses of aducanumab but not placebo. (Reprinted with permission of (30).)

(Left) ¹⁸F-FEOBV PET, MR, and overlay images from healthy control subject. (Reprinted from (35).) (Right) Age-related reduced Vesicular acetylcholine transporter binding reductions (Reprinted from (39).)

⁶⁸Ga-PSMA-11 PET before and after treatment with ¹⁷⁷Lu-PSMA-617. (Reprinted from (42).)